Send to

Choose Destination
Vaccine. 2007 Apr 20;25(16):3075-9. Epub 2007 Jan 22.

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

Author information

Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina 1, 53100 Siena, Italy.


To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of >1,000,000 people under 20 years. After the three-dose course 75% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center